- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00412178
Effect of Mobile Communication With a Cellular Phone With a Glucometer on Glucose Control in Type 2 Diabetic Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Various strategies using electronic technologies or educational programs have been proposed to improve the quality and efficiency of care for people with diabetes. In the previous study, we introduced a new bidirectional communication tool for diabetes management termed the Internet-Based Glucose Monitoring System (IBGMS), and demonstrated its short-term and long-term effects on glycemic control in type 2 diabetic patients. Other researchers have also showed the effectiveness of telecommunication between health-care providers and patients for maintaining appropriate blood glucose control. These systems allow patients to send data to doctors, identify specific problems and receive recommendations from health-care providers more frequently and with fewer time and place limitations than at traditional face-to-face outpatient clinics. With the IBGMS, physicians can monitor patients' self-monitored blood glucose data at regular intervals, and patients can communicate with their physicians whenever they have any questions. Although bidirectional interactive communications between physicians and patients can be achieved with the IBGMS, there remain time and place limitations. Patients must connect to the Internet using their personal computer to input their data or questions on the IBGMS, while physicians only visit the website at regular intervals unless they have received questions from patients.
To improve the efficiency of communication, we linked the IBGMS to the short message service (SMS) delivered by cellular phone. The patients sent their data to doctors through the IBGMS and then received the doctors' recommendations about adjustment of drug dosage and other related data on the cellular phone. This system improved the efficiency of communication and patients' satisfaction also slightly increased. However, patients were still limited by place and time when sending questions and blood glucose-monitoring data.
Recently, cellular phones have been developed that can measure blood glucose level and transmit data directly to a web server (Diabetes Phone). The combination of a glucometer with the cellular phone function makes it easier for patients to report their self-monitored blood glucose (SMBG) levels and receive feedback from their doctors. However, it was not known how effective this cellular phone glucose-monitoring system would be for control of blood glucose levels, compared to the IBGMS tested previously. We investigated the effectiveness of the diabetes phone for blood glucose control and compared it with that of the IBGMS.
Study Type
Enrollment
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Seoul, Korea, Republic of, 137-040
- Kangnam St. Mary's Hospital, The Catholic University of Korea
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with type 2 diabetes mellitus who were able to operate the Internet and to communicate through a mobile phone using the short message service
Exclusion Criteria:
- Significant disease conditions such as symptomatic heart failure, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels more than twice the normal level, renal disease and creatinine level greater than 1.5 mg/dL.
- Patients were also excluded if they participated in other programs that provided information or education about diabetes management from any Internet websites or by any cellular phones other than ours.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
HbA1c
|
Secondary Outcome Measures
Outcome Measure |
---|
Compliance
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Jae-Hyoung Cho, Instructor, Kangnam St. Mary's Hospital, The Catholic University of Korea
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CMC
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
AstraZenecaRecruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
-
Newsoara Biopharma Co., Ltd.RecruitingT2DM (Type 2 Diabetes Mellitus)China
Clinical Trials on telecommunication based glucose monitoring system
-
Abbott Diabetes CareCompletedType 2 Diabetes MellitusFrance, United Kingdom, Germany
-
Abbott Diabetes CareCompletedType 1 Diabetes MellitusAustria, Netherlands, Germany, Spain, Sweden
-
Endocrine Research SocietyCompletedType 2 Diabetes MellitusCanada
-
Abbott Diabetes CareCompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1United States
-
Abbott Diabetes CareCompletedDiabetes MellitusUnited Kingdom
-
Tomsk National Research Medical Center of the Russian...RecruitingCOVID-19 | Risk Factors | Polypharmacy | Drug Interactions | Self MedicationRussian Federation
-
Scripps Whittier Diabetes InstituteDexCom, Inc.TerminatedDiabetes Mellitus, Type 2United States
-
Abbott Diabetes CareCompletedType 2 Diabetes MellitusUnited States
-
Senseonics, Inc.CompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus | Diabetes Mellitus, Type 1United States
-
B. Braun Melsungen AGInstitut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft...Completed